Interview with Harald Sprenger, CEO Pharmaceutical Research and Manufacturers Association (PReMA)

Interview with Harald Sprenger, CEO Pharmaceutical Research and Manufacturers Association (PReMA)

 

Thailand has one of Asia’s most advanced healthcare sectors, ranking eighth globally in 2026 and first in ASEAN according to Numbeo. However, healthcare reform is becoming increasingly important as the country faces a rapidly ageing population and rising healthcare costs. Earlier this year, the Ministry of Public Health set out a bold vision at PReMA’s Extraordinary General Meeting to position Thailand as a regional health and bioscience hub. What strengths does Thailand have in pharmaceuticals and R&D and which areas offer the greatest potential for the country to emerge as a regional pharmaceutical and bioscience hub?

Thailand has very good healthcare capabilities and education, with excellent medical faculties, hospitals, doctors and expertise. Around 17 million people are covered by universal healthcare, so basic healthcare is guaranteed. However, as the population ages and people live longer, demand for healthcare is increasing and becoming more expensive for the government. Therefore they are looking for ways to improve the system while ensuring sustainable funding. Thailand is also looking at what other countries in the region are doing, including the potential role of private insurance. This is relatively new for Thailand, but the government is interested in learning from other countries and exploring what could work better here.

We have around 30 members, all research-based pharmaceutical companies. We don’t have generic manufacturers, so our members are important partners in research and innovation. Thailand has strong hospitals and doctors, but the government wants to expand clinical research beyond university hospitals, which have already reached capacity, to Ministry of Public Health hospitals, including those in rural areas. Our members can help build those capabilities. Thailand also faces strong competition from countries such as Malaysia and Vietnam, while Korea is already highly advanced. Our members’ headquarters in the U.S. and Europe have to decide where to invest in clinical trials, so we work with the government to identify what Thailand needs to attract more research.

Better coordination could make the country even more competitive. We recently signed a memorandum of understanding (MOU) with the Thai FDA and other government agencies to work together on attracting clinical trials and research. One area we are looking at is speeding up approval timelines, including the ethical approval process. The process used to take a long time because companies had to submit separate applications to different bodies. Now, they are aligning the process so there is a single application and a fast-track system. I recently spoke with the Secretary-General, who said they are looking at reducing clinical-trial approval timelines by 50 percent.

Companies conducting clinical trials would also receive fast-track regulatory approval when bringing their products to market. These measures could make Thailand much more attractive for research investment. At the same time, we need to address sustainable healthcare financing. We are working with the Ministry of Health on an MOU to attract more investment and develop a more sustainable funding model. It’s not easy, with many stakeholders involved, but we are working to bring everyone together and align on what is needed.

 

You recently highlighted several reforms needed to strengthen the healthcare industry, including a greater focus on preventive care, sustainable healthcare financing and stronger collaboration through a “Team Thailand” platform. Which reforms are now most critical and how does your five-year strategy aim to strengthen Thailand’s pharmaceutical and healthcare sectors?

About 20 percent of healthcare spending goes to pharmaceuticals. We are explaining to the government that early treatment with the right medicines can prevent much higher costs later. If you wait until people become seriously ill, you face hospitalization, surgery and long-term care costs. There is also the economic impact on families when people have to take time off work to care for sick relatives.

Evidence shows that treating patients early can significantly reduce these costs and the government is very open to this approach. We have identified several therapeutic areas that are particularly important for Thailand. Cancer, diabetes and similar diseases are areas where pharmaceutical companies have a lot of data we can share with the government. We believe part of the pressure on healthcare financing comes from spending resources inefficiently. The government is already investing heavily in prevention and encouraging healthier lifestyles. We also believe that early diagnosis and treatment can help use healthcare resources more effectively. We are working with medical associations, patient groups and government agencies to promote this approach. It is still early, but we have already made significant progress.

 

PReMA is a non-profit organization that acts as the unified voice for research-driven pharmaceutical developers operating in Thailand. The association works through three strategic taskforces to promote ethical business practices, support resilient regulatory systems and deepen industry engagement. PReMA also recently relocated its offices to One City Centre in Bangkok. Can you give Newsweek readers a brief overview of PReMA, its current mandate and the role its three strategic taskforces play in supporting Thailand’s pharmaceutical industry?

We have 30 members, all research-based, innovative pharmaceutical companies, employing around 7,000–8,000 people in Thailand and investing significantly in the country. Our contribution goes beyond medicines. Our members also support medical education through conferences and exchanges with healthcare professionals. PReMA has been around for 55 years, but when I joined two years ago, I felt our relationship with the government needed to change. Instead of telling the government what to do, we now focus on working together toward shared goals: healthier people and a stronger Thai economy. This approach has significantly improved our relationship with the authorities. We now have much closer access to the Ministry of Health and the Thai FDA and our members are increasingly working with the government on initiatives such as voluntary licensing, investment and potentially manufacturing innovative medicines in Thailand. Developing talent and innovation will be critical as Thailand prepares for major demographic change.

 

Developing local talent and innovation will be critical as Thailand prepares for major demographic change. The World Bank estimates that the country’s working-age population will decline from 71 percent of the population in 2020 to 56 percent by 2060, reducing the active workforce by nearly 30 percent. The growing presence of multinational pharmaceutical companies is creating valuable opportunities for knowledge transfer and skills development. What are the biggest talent challenges facing Thailand’s pharmaceutical sector and how can greater collaboration with multinational companies help develop the skills and expertise needed for future growth?

Our companies operate around the world and work closely with governments and health authorities, giving us valuable experience in what works and what doesn’t. Rather than Thailand reinventing the wheel, we can use our global network to share that knowledge and connect Thai officials with their counterparts in other countries. PReMA is also involved in the Asia-Pacific industry association network, where industry groups from countries such as Japan, China and Vietnam exchange experiences. We bring government officials into these discussions so they can learn directly from other markets.

We also have an important role in developing talent. Attracting more clinical trials to Thailand will create opportunities to train and educate medical professionals. The number of clinical trials is forecast to double by 2033, with our member companies expected to invest around $1.6 billion. Studies suggest that every dollar spent on clinical trials generates about $3 for the economy, potentially creating nearly $5 billion in additional economic activity. The government recognizes this opportunity and we are working closely together to make it happen. If we can treat people earlier and prevent diseases from becoming more serious, we can also reduce the burden on family caregivers. In Asia, families often care for sick relatives, which can force working-age people to take time off. Reducing that burden would help address the growing shortage of talent.

 

Thailand’s Minister of Public Health, Pattana Promphat, has signaled a strong government focus on digitizing the healthcare value chain, from smart manufacturing to the adoption of AI and automation in treatment. This comes alongside growing local investment in biotechnology. How are technologies such as AI and automation transforming pharmaceutical research and manufacturing and how are industry watchdogs like PReMA and the government helping the industry take advantage of these new tools?

We have been saying for some time that Thailand needs to digitalize more. Many government processes are still paper-based, which makes regulatory applications cumbersome and slow. Our member companies are already highly digitalized and using AI extensively, so we have started sharing best practices with the government. The Thai FDA is moving in the right direction and more applications for new drugs can now be submitted digitally. We recently met with the secretary-general to discuss how to speed up regulatory approvals. AI could help process the large amount of data involved, which is currently handled manually. We’ve agreed to establish a task force with the Thai FDA to explore how AI can be used to make the process faster and more efficient.

 

Thailand’s investment market is booming, with investment applications reaching a record $43.7 billion baht across 1,300 projects in the first half of 2026. The government has also announced plans to reform more than 7,000 business regulations to reduce bureaucracy and strengthen Thailand’s ability to compete for global capital. How important have foreign investment and multinational companies been to the development of Thailand’s pharmaceutical and bioscience industries and what more is needed to attract greater international investment?

Recently, one of our member companies signed a voluntary licensing agreement that will allow a HIV vaccine previously made abroad to be produced locally in Thailand. The company will also share its expertise with the Thai government, supporting talent development and helping strengthen local manufacturing capabilities. We expect more agreements like this in the future. Thailand faces strong competition from other markets, while bureaucracy can make processes slow.

The government recognizes this challenge and we are working together to find more efficient ways to move these initiatives forward. Another important factor is predictability. In the past, companies have been hesitant to invest because they were uncertain about what might change in six months or a year, particularly given Thailand’s rapid changes in government. Investors need a stable and predictable environment, with clear communication and advance notice of major policy changes. This is something we are encouraging the government to take seriously.

 

Where do you see the strongest opportunities for U.S. investors and companies within Thailand’s pharmaceutical, bioscience and R&D ecosystem and why is now an attractive time to participate?

Thailand’s biggest advantage compared with other countries in the region is the excellent quality of its healthcare professionals and hospitals. They can compete with the best in Europe and the U.S. The foundation is already there. If Thailand can improve coordination between stakeholders, speed up clinical-trial and regulatory approvals and reduce bureaucracy, there is huge potential to strengthen an already excellent healthcare system.

 

You stepped into the role of CEO during a period of significant change for PReMA. Since taking the helm, you have overseen the restructuring of the association’s internal team and helped sharpen its strategic direction as it responds to a rapidly changing pharmaceutical and healthcare landscape. What have been your main priorities since taking the helm of PReMA and what impact would you like the association to have on Thailand’s healthcare and pharmaceutical industry over the coming years?

After 55 years, PReMA needed a fresh start. We have done that by moving offices, building a young and talented team and, most importantly, changing how we engage with the outside world. Traditionally, pharmaceutical associations have been seen as focused on prices and complaints. We believe there is a better approach: we all want healthier patients and a stronger Thai economy. We see ourselves as part of Team Thailand and we want to find win-win solutions with the government. Our global network gives us valuable expertise that we can bring to Thailand, from disease treatment to healthcare financing and access.

We are ready to work with the government on improving access and developing sustainable financing solutions. At the same time, predictability and transparency are essential. Companies need to understand what the environment will look like in the medium to long term. With greater cooperation and stability, we can achieve much more together. With this new vision for PReMA, we are focusing on three strategic priorities: early treatment; creating a better environment for investment in clinical research, trials and manufacturing; and sustainable healthcare financing. These three pillars are important for addressing Thailand’s aging population and economic challenges. By focusing on them, I believe we can make a real impact in Thailand.

 

What’s your final message to the readers of Newsweek?

Thailand is a great country—the Land of Smiles. I have lived in Asia for 15 years and chose to move to Thailand because I love it. Thailand has everything it needs to succeed and with the right approach, I believe it can achieve even more.